Pain Management Drugs Market by Drug Class (NSAIDs, Anesthetics, Anticonvulsants, Antimigraine Agents, Antidepressants, Opioids [Tramadol, Hydrocodone, Oxycodone, and Others], and Nonnarcotic Analgesics) and Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Pain, Migraine, and Fibromyalgia) - Global Opportunity Analysis and Industry Forecast, 2017-2023
Pain Management Drugs Market by Drug Class (NSAIDs, Anesthetics, Anticonvulsants, Antimigraine Agents, Antidepressants, Opioids [Tramadol, Hydrocodone, Oxycodone, and Others], and Nonnarcotic Analgesics) and Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Pain, Migraine, and Fibromyalgia) - Global Opportunity Analysis and Industry Forecast, 2017-2023

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or Email: pdb@bioportfolio.co.uk
Pain management is a branch of medicine, which employs approach to ease the suffering and improve the quality of life of individuals suffering from pain. Pain can be classified based on its occurrence and duration along with the affected body part. First line of treatment for pain management is pharmaceutical therapeutics or pain killer drugs, most of which are well-known brands. The global pain management drugs market was valued at $58,577 million in 2016, and is estimated to reach $77,131 million by 2023, registering a CAGR of 4% from 2017 to 2023.

Rise in geriatric population is the major factor that drives the growth of the global pain management market, as aged people are more prone to suffer from joint pain and other chronic conditions. Moreover, surge in prevalence of chronic diseases such as cancer, diabetic neuropathy, and osteoarthritis propels the market growth.

Furthermore, increase in number of surgical procedures and rise in healthcare expenditure are expected to fuel the growth of the market. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth.

The global pain management drugs market is segmented based on drug class, indication, and geography. On the basis of drug class, the market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, antimigraine agents, antidepressants, opioids, and nonnarcotic analgesics. Opioids are further classified into tramadol, hydrocodone, oxycodone, and others (fentanyl, morphine, meperidine, codeine, and methadone). By indication, the market is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, and fibromyalgia. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

This report offers a detailed quantitative analysis of the current & future market trends from 2016 to 2023 to identify the prevailing opportunities.

The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.

The global pain management drugs market is comprehensively analyzed with respect to drug class, indication, and geography.
In-depth analysis based on geography facilitates to analyze the regional trends to assist in strategic business planning.

The developmental strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.

KEY PLAYERS PROFILED

Novartis AG
Eli Lilly & Company
Abbott Laboratories
Endo Health Solutions, Inc.
Purdue Pharma L.P.
Pfizer, Inc.
F. Hoffmann La Roche Ltd.
Merck & Co. Inc.
Johnson & Johnson
GlaxoSmithKline Plc.

KEY MARKET SEGMENTS

By Drug Class

NSAIDs
Anesthetics
Anticonvulsants
Antimigraine Agents
Antidepressants
Opioids
Tramadol
Hydrocodone
Oxycodone
Others
Nonnarcotic Analgesics

By Indication
Arthritic Pain
Neuropathic Pain
Cancer Pain
Chronic Back Pain
Postoperative Pain
Migraine
Fibromyalgia

By Geography

North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
Rest of Asia-Pacific
LAMEA
Brazil
Republic of South Africa
Saudi Arabia
Rest of LAMEA
The other players operating in the pain management drugs market include (companies not profiled in the report):

Allergen Inc.
Bayer AG
Bristol-Myers Squibb
Valeant Pharmaceuticals International Inc.
Boehringer Ingelheim
Sorrento Therapeutics
WEX Pharmaceuticals
Zynerba Pharmaceuticals

Additional Details

Publisher: Allied Market Research
Reference: LI 0404
Number of Pages: 170
Report Format: PDF
Publisher Information:
Table Of Contents for Pain Management Drugs Market by Drug Class (NSAIDs, Anesthetics, Anticonvulsants, Antimigraine Agents, Antidepressants, Opioids [Tramadol, Hydrocodone, Oxycodone, and Others], and Nonnarcotic Analgesics) and Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Pain, Migraine, and Fibromyalgia) - Global Opportunity Analysis and Industry Forecast, 2017-2023 [Report Updated: 01-10-2017]
6.4. ASIA-PACIFIC

6.4.1. Key market trends

6.4.2. Key growth factors and opportunities

6.4.3. Market size and forecast by country

6.4.4. Market size and forecast by drug class

6.4.5. Market size and forecast by indication

6.4.5.1. Japan market size and forecast by drug class

6.4.5.2. Japan market size and forecast by indication

6.4.5.3. China market size and forecast by drug class

6.4.5.4. China market size and forecast by indication

6.4.5.5. Australia market size and forecast by drug class

6.4.5.6. Australia market size and forecast by indication

6.4.5.7. South Korea market size and forecast by drug class

6.4.5.8. South Korea market size and forecast by indication

6.4.5.9. India market size and forecast by drug class

6.4.5.10. India market size and forecast by indication

6.4.5.11. Taiwan market size and forecast by drug class

6.4.5.12. Taiwan market size and forecast by indication

6.4.5.13. Rest of Asia-Pacific market size and forecast by drug class

6.4.5.14. Rest of Asia-Pacific market size and forecast by indication

6.5. LAMEA

6.5.1. Key market trends

6.5.2. Key growth factors and opportunities

6.5.3. Market size and forecast by country

6.5.4. Market size and forecast by drug class

6.5.5. Market size and forecast by indication

6.5.5.1. Brazil market size and forecast by drug class

6.5.5.2. Brazil market size and forecast by indication

6.5.5.3. South Africa market size and forecast by drug class

6.5.5.4. South Africa market size and forecast by indication

6.5.5.5. Saudi Arabia market size and forecast by drug class

6.5.5.6. Saudi Arabia market size and forecast by indication

6.5.5.7. Rest of LAMEA market size and forecast by drug class

6.5.5.8. Rest of LAMEA market size and forecast by indication

CHAPTER 7 COMPANY PROFILES

7.1. NOVARTIS AG

7.1.1. Company overview

7.1.2. Company snapshot

7.1.3. Operating business segments

7.1.4. Business performance

7.1.5. Key strategic moves and developments

7.2. ELI LILLY & COMPANY

7.2.1. Company overview

7.2.2. Company snapshot

7.2.3. Operating business segments

7.2.4. Business performance

7.2.5. Key strategic moves and developments

7.3. ABBOTT LABORATORIES, INC.

7.3.1. Company overview

7.3.2. Company snapshot

7.3.3. Operating business segments

7.3.4. Business performance

7.3.5. Key strategic moves and developments

7.4. ENDO HEALTH SOLUTIONS, INC.

7.4.1. Company overview

7.4.2. Company snapshot

7.4.3. Operating business segments

7.4.4. Business performance

7.4.5. Key strategic moves and developments

7.5. PURDUE PHARMA L.P.

7.5.1. Company overview

7.5.2. Company snapshot

7.5.3. Operating business segments

7.5.4. Business performance

7.5.5. Key strategic moves and developments

7.6. PFIZER, INC.

7.6.1. Company overview

7.6.2. Company snapshot

7.6.3. Operating business segments

7.6.4. Business performance

7.6.5. Key strategic moves and developments

7.7. F. HOFFMANN LA ROCHE LTD.

7.7.1. Company overview

7.7.2. Company snapshot

7.7.3. Operating business segments

7.7.4. Business performance

7.7.5. Key strategic moves and developments

7.8. MERCK & CO.

7.8.1. Company overview

7.8.2. Company snapshot

7.8.3. Operating business segments

7.8.4. Business performance

7.8.5. Key strategic moves and developments

7.9. JOHNSON & JOHNSON

7.9.1. Company overview

7.9.2. Company snapshot

7.9.3. Operating business segments

7.9.4. Business performance

7.9.5. Key strategic moves and developments

7.10. GLAXOSMITHKLINE PLC.

7.10.1. Company overview

7.10.2. Company snapshot

7.10.3. Operating business segments

7.10.4. Business performance

7.10.5. Key strategic moves and developments
List Of Tables in Pain Management Drugs Market by Drug Class (NSAIDs, Anesthetics, Anticonvulsants, Antimigraine Agents, Antidepressants, Opioids [Tramadol, Hydrocodone, Oxycodone, and Others], and Nonnarcotic Analgesics) and Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Pain, Migraine, and Fibromyalgia) - Global Opportunity Analysis and Industry Forecast, 2017-2023 [Report Updated: 01-10-2017]

TABLE 1. GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)

TABLE 2. PAIN MANAGEMENT DRUGS MARKET USING NSAIDS, BY REGION, 2016-2023 ($MILLION)

TABLE 3. PAIN MANAGEMENT DRUGS MARKET USING ANESTHETICS, BY REGION, 2016-2023 ($MILLION)

TABLE 4. PAIN MANAGEMENT DRUGS MARKET USING ANTICONVULSANTS, BY REGION, 2016-2023 ($MILLION)

TABLE 5. PAIN MANAGEMENT DRUGS MARKET USING ANTI-MIGRAINE AGENTS, BY REGION, 2016-2023 ($MILLION)

TABLE 6. PAIN MANAGEMENT DRUGS MARKET USING ANTIDEPRESSANTS, BY REGION, 2016-2023 ($MILLION)

TABLE 7. PAIN MANAGEMENT DRUGS MARKET USING OPIOIDS, BY REGION, 2016-2023 ($MILLION)

TABLE 8. PAIN MANAGEMENT DRUGS MARKET USING NON-NARCOTIC ANALGESICS, BY REGION, 2016-2023 ($MILLION)

TABLE 9. GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)

TABLE 10. PAIN MANAGEMENT DRUGS MARKET FOR ARTHRITIC PAIN, BY REGION, 2016-2023 ($MILLION)

TABLE 11. PAIN MANAGEMENT DRUGS MARKET FOR NEUROPATHIC PAIN, BY REGION, 2016-2023 ($MILLION)

TABLE 12. PAIN MANAGEMENT DRUGS MARKET FOR CANCER PAIN, BY REGION, 2016-2023 ($MILLION)

TABLE 13. PAIN MANAGEMENT DRUGS MARKET FOR CHRONIC BACK PAIN, BY REGION, 2016-2023 ($MILLION)

TABLE 14. PAIN MANAGEMENT DRUGS MARKET FOR POST-OPERATIVE PAIN, BY REGION, 2016-2023 ($MILLION)

TABLE 15. PAIN MANAGEMENT DRUGS MARKET FOR MIGRAINE, BY REGION, 2016-2023 ($MILLION)

TABLE 16. PAIN MANAGEMENT DRUGS MARKET FOR FIBROMYALGIA, BY REGION, 2016-2023 ($MILLION)

TABLE 17. PAIN MANAGEMENT DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)

TABLE 18. NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)

TABLE 19. NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>2016-2023 ($Million)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 20</td>
<td>North America Pain Management Drugs Market, by Indications</td>
<td></td>
</tr>
<tr>
<td>Table 21</td>
<td>U.S. Pain Management Drugs Market, by Drug Class</td>
<td></td>
</tr>
<tr>
<td>Table 22</td>
<td>U.S. Pain Management Drugs Market, by Indications</td>
<td></td>
</tr>
<tr>
<td>Table 23</td>
<td>Canada Pain Management Drugs Market, by Drug Class</td>
<td></td>
</tr>
<tr>
<td>Table 24</td>
<td>Canada Pain Management Drugs Market, by Indications</td>
<td></td>
</tr>
<tr>
<td>Table 25</td>
<td>Mexico Pain Management Drugs Market, by Drug Class</td>
<td></td>
</tr>
<tr>
<td>Table 26</td>
<td>Mexico Pain Management Drugs Market, by Indications</td>
<td></td>
</tr>
<tr>
<td>Table 27</td>
<td>Europe Pain Management Drugs Market, by Country</td>
<td></td>
</tr>
<tr>
<td>Table 28</td>
<td>Europe Pain Management Drugs Market, by Drug Class</td>
<td></td>
</tr>
<tr>
<td>Table 29</td>
<td>Europe Pain Management Drugs Market, by Indications</td>
<td></td>
</tr>
<tr>
<td>Table 30</td>
<td>U.K. Pain Management Drugs Market, by Drug Class</td>
<td></td>
</tr>
<tr>
<td>Table 31</td>
<td>U.K. Pain Management Drugs Market, by Indications</td>
<td></td>
</tr>
<tr>
<td>Table 32</td>
<td>France Pain Management Drugs Market, by Drug Class</td>
<td></td>
</tr>
<tr>
<td>Table 33</td>
<td>France Pain Management Drugs Market, by Indications</td>
<td></td>
</tr>
<tr>
<td>Table 34</td>
<td>Germany Pain Management Drugs Market, by Drug Class</td>
<td></td>
</tr>
<tr>
<td>Table 35</td>
<td>Germany Pain Management Drugs Market, by Indications</td>
<td></td>
</tr>
<tr>
<td>Table 36</td>
<td>Italy Pain Management Drugs Market, by Drug Class</td>
<td></td>
</tr>
<tr>
<td>Table 37</td>
<td>Italy Pain Management Drugs Market, by Indications</td>
<td></td>
</tr>
<tr>
<td>Table 38</td>
<td>Spain Pain Management Drugs Market, by Drug Class</td>
<td></td>
</tr>
<tr>
<td>Table 39</td>
<td>Spain Pain Management Drugs Market, by Indications</td>
<td></td>
</tr>
<tr>
<td>Table 40</td>
<td>Rest of Europe Pain Management Drugs Market, by Drug Class</td>
<td></td>
</tr>
<tr>
<td>Table 41</td>
<td>Rest of Europe Pain Management Drugs Market, by Indications</td>
<td></td>
</tr>
<tr>
<td>Table 42</td>
<td>Asia-Pacific Pain Management Drugs Market, by Country</td>
<td></td>
</tr>
<tr>
<td>Table 43</td>
<td>Asia-Pacific Pain Management Drugs Market, by Drug Class</td>
<td></td>
</tr>
<tr>
<td>Table 44</td>
<td>Asia-Pacific Pain Management Drugs Market, by Indications</td>
<td></td>
</tr>
<tr>
<td>Table 45</td>
<td>Japan Pain Management Drugs Market, by Drug Class</td>
<td></td>
</tr>
<tr>
<td>Table 46</td>
<td>Japan Pain Management Drugs Market, by Indications</td>
<td></td>
</tr>
<tr>
<td>Table 47</td>
<td>China Pain Management Drugs Market, by Drug Class</td>
<td></td>
</tr>
<tr>
<td>Table 48</td>
<td>China Pain Management Drugs Market, by Indications</td>
<td></td>
</tr>
<tr>
<td>Table 49</td>
<td>Australia Pain Management Drugs Market, by Drug Class</td>
<td></td>
</tr>
<tr>
<td>Table 50</td>
<td>Australia Pain Management Drugs Market, by Indications</td>
<td></td>
</tr>
</tbody>
</table>
TABLE 51. SOUTH KOREA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 52. SOUTH KOREA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 53. INDIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 54. INDIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 55. TAIWAN PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 56. TAIWAN PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 57. REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 58. REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 59. LAMEA PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 60. LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 61. LAMEA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 62. BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 63. BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 64. SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 65. SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 66. SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 67. SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
TABLE 68. REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 69. REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2016-2023 ($MILLION)
List Of Figures, Charts and Diagrams in Pain Management Drugs Market by Drug Class (NSAIDs, Anesthetics, Anticonvulsants, Antimigraine Agents, Antidepressants, Opioids [Tramadol, Hydrocodone, Oxycodone, and Others], and Nonnarcotic Analgesics) and Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Pain, Migraine, and Fibromyalgia) - Global Opportunity Analysis and Industry Forecast, 2017-2023 [Report Updated: 01-1-2017]

FIGURE 1. SEGMENTATION OF GLOBAL PAIN MANAGEMENT DRUGS MARKET
FIGURE 2. TOP INVESTMENT POCKETS IN GLOBAL PAIN MANAGEMENT DRUGS MARKET
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 5. TOP WINNING STRATEGIES: NATURE AND COMPANY
FIGURE 6. BARGAINING POWER OF BUYERS
FIGURE 7. BARGAINING POWER OF SUPPLIERS
FIGURE 8. THREAT OF NEW ENTRANTS
FIGURE 9. THREAT OF SUBSTITUTION
FIGURE 10. COMPETITIVE RIVALRY
FIGURE 11. RESTRAINTS AND DRIVERS: GLOBAL PAIN MANAGEMENT DRUGS MARKET
FIGURE 12. U.S. PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 13. CANADA PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 14. MEXICO PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 15. UK PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 16. FRANCE PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 17. GERMANY PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 18. ITALY PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 19. SPAIN PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 20. REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 21. JAPAN PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 22. CHINA PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 23. AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 24. SOUTH KOREA PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 25. INDIA PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 26. TAIWAN PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 27. REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 28. BRAZIL PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 29. SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 30. SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
FIGURE 31. REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, 2016-2023 ($MILLION)
How to Buy...

Pain Management Drugs Market by Drug Class (NSAIDs, Anesthetics, Anticonvulsants, Antimigraine Agents, Antidepressants, Opioids [Tramadol, Hydrocodone, Oxycodone, and Others], and Nonnarcotic Analgesics) and Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Pain, Migraine, and Fibromyalgia) - Global Opportunity Analysis and Industry Forecast, 2017-2023 [Report Updated: 01-10-2017]

Option 1 - Online
Go to our website and pay online with any major debit or credit card:
https://www.bioportfolio.co.uk/product/152934

Option 2 - Request a Proforma Invoice
Fill in the details below, and either Scan this page and email it to us at pdb@bioportfolio.co.uk or Fax it to us at +44 (0)1305 791844.We will send you a Proforma Invoice and deliver your report on settlement.

Your Name: ........................................................................................................................................................................
Job Title: ...................................................................................................................................................................................
Your Email: ..........................................................................................................................................................................
Your Contact Phone: ..............................................................................................................................................................
Company Name: ....................................................................................................................................................................
Address: ......................................................................................................................................................................................
Post/Zip Code: ........................................................................................................................................................................
Country: ....................................................................................................................................................................................
P.O. Number: ........................................................................................................................................................................
Any Other Instructions: ...............................................................................................................................................................

Pricing Options: (please tick one)
○ $5370 | Single User Price
○ $7800 | Enterprise License Price

Payment Options: (please tick one)
○ Online Credit Card (we will email you the invoice with a payment link)
○ Direct Wire Transfer (we will email you the invoice with our bank details)

Authorising Signature: ..............................................................................................................................................................

Option 3 - Phone Us on +44 (0)7887 945155
We will be delighted to give you our personal attention.